Philogen SpA PHIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €19.65
- Day Range
- €19.70–19.90
- 52-Week Range
- €16.30–21.90
- Bid/Ask
- €19.70 / €19.90
- Market Cap
- €793.71 Mil
- Volume/Avg
- 2,380 / 7,992
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 345.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.15%
Company Profile
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 174
- Website
- https://www.philogen.com
Comparables
Valuation
|
Metric
|
PHIL
|
02509
|
AUPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.64 | 34.29 | 2.68 |
Price/Sales | 345.79 | 105.20 | 4.74 |
Price/Cash Flow | — | — | — |
Price/Earnings
PHIL
02509
AUPH
Financial Strength
|
Metric
|
PHIL
|
02509
|
AUPH
|
|---|---|---|---|
Quick Ratio | 4.98 | 1.70 | 4.63 |
Current Ratio | 5.22 | 1.86 | 5.33 |
Interest Coverage | −55.09 | −18.42 | −11.69 |
Quick Ratio
PHIL
02509
AUPH
Profitability
|
Metric
|
PHIL
|
02509
|
AUPH
|
|---|---|---|---|
Return on Assets (Normalized) | −26.47% | −47.40% | −2.14% |
Return on Equity (Normalized) | −35.28% | −341.08% | −3.06% |
Return on Invested Capital (Normalized) | −30.74% | −56.34% | −4.73% |
Return on Assets
PHIL
02509
AUPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xbntgdhqxf | Dzhd | $526.2 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vgkpkvpt | Gxtqhh | $115.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ywlswqxxp | Crfpcs | $109.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vhngrmtw | Rbrtx | $34.2 Bil | |||
| argenx SE ADR
ARGX
| Mvzxflbwz | Qzyr | $31.5 Bil | |||
| BioNTech SE ADR
BNTX
| Cxpdmbqhc | Mvqgw | $28.9 Bil | |||
| Moderna Inc
MRNA
| Vkfzjsxr | Smrfh | $22.6 Bil | |||
| United Therapeutics Corp
UTHR
| Bhxwmfwmm | Rwts | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ljxzzwkdc | Nnxyns | $13.1 Bil | |||
| Incyte Corp
INCY
| Bfqqwqn | Zzrfjkx | $12.7 Bil |
United States